Simplified antimalarial therapeutic monitoring: using the day-7 drug level?

Trends in Parasitology

Volumn 24, Issue 4, 2008, Pages 159-163

  White, Nicholas J ^a,b   Stepniewska, Kasia ^a,b   Barnes, Karen ^c   Price, Ric N ^b,d   Simpson, Julie ^e  

^a MAHIDOL UNIVERSITY   (Thailand)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; BENFLUMETOL; CHLOROQUINE; PIPERAQUINE;

ANTIMALARIAL ACTIVITY; ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MONITORING; DRUG RESPONSE; HUMAN; MALARIA FALCIPARUM; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE;

ANIMALS; ANTIMALARIALS; AREA UNDER CURVE; ARTEMISININS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; MALARIA; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 41349093931     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2008.01.006     Document Type: Article

References (26)

1. World Health Organisation (2006) Guidelines for the treatment of malaria, World Health Organization, Geneva
2. World Health Organisation (2002) Monitoring antimalarial drug resistance. Report of a WHO consultation, WHO/CDS/CSR/EPH/2002.17, Geneva
3. White N.J. Assessment of the pharmacodynamic properties of the antimalarial drugs in vivo. Antimicrob. Agents Chemother. 41 (1997) 1413-1422
4. Day N.P.J., et al. Clearance kinetics of parasites and pigment-containing leukocytes in severe malaria. Blood 88 (1996) 4694-4700
5. Simpson J.A., et al. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clin. Pharmacol. Ther. 66 (1999) 472-484
6. Newton P.N., et al. A comparison of artesunate alone with combined artesunate and quinine in the parenteral treatment of acute falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 95 (2001) 519-523
7. White N.J. Antimalarial drug resistance. J. Clin. Invest. 113 (2004) 1084-1092
8. Hoshen M.B., et al. Mathematical modelling of malaria chemotherapy: combining artesunate and mefloquine. Parasitology 124 (2002) 9-15
9. Gustafsson L.L., et al. Disposition of chloroquine in man after single intravenous and oral doses. Br. J. Clin. Pharmacol. 15 (1983) 471-479
10. Hung T.Y., et al. Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol. 57 (2004) 253-262
11. Tarning J., et al. Population pharmacokinetics of piperaquine after two different treatment regimens of dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand. Antimicrob. Agents Chemother. 52 (2008) 1052-1061
12. Sidhu J.S., et al. Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br. J. Clin. Pharmacol. 45 (1998) 347-354
13. White N.J., et al. Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin. Pharmacokinet. 37 (1999) 105-125
14. Ezzet F., et al. The pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute uncomplicated falciparum malaria. Antimicrob. Agents Chemother. 44 (2000) 697-704
15. Barnes K.I., et al. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin. Pharmacol. Ther. 80 (2006) 582-596
16. Price R.N., et al. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob. Agents Chemother. 51 (2007) 4090-4097
17. Bergqvist Y., et al. Sulfadoxine assay using capillary blood samples dried on filter paper suitable for monitoring of blood concentrations in the field. Ther. Drug Monit. 9 (1987) 203-207
18. van Vugt M., et al. The relationship between capillary and venous concentrations of lumefantrine (benflumetol). Trans. R. Soc. Trop. Med. Hyg. 92 (1998) 564-565
19. ter Kuile F.O., et al. Comparison of capillary whole blood, venous whole blood, and plasma concentrations of mefloquine, halofantrine, and des-butyl halofantrine measured by high performance liquid chromatography. Am. J. Trop. Med. Hyg. 51 (1994) 778-784
20. Ronn A.M., et al. High-performance liquid chromatography determination of dapsone, monoacetyldapsone, and pyrimethamine in filter paper blood spots. Ther. Drug Monit. 17 (1995) 79-83
21. Price R. Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria. Antimicrob. Agents Chemother. 43 (1999) 341-346
22. Smithuis F., et al. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 367 (2006) 2075-2085
23. Hietala S.F., et al. Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J. Pharmacokinet. Pharmacodyn. 34 (2007) 669-686
24. Hussein Z., et al. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Clin. Pharmacol. Ther. 61 (1997) 518-530
25. Simpson J.A., et al. Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone. Br. J. Clin. Pharmacol. 61 (2006) 289-300
26. Simpson J.A., et al. How can we do pharmacokinetic studies in the tropics?. Trans. R. Soc. Trop. Med. Hyg. 95 (2001) 347-351